Caesars Entertainment misses Q2 earnings expectations, shares edge lower
In a recent SEC filing, COMPASS Pathways plc, a pharmaceutical company specializing in psychedelic medicine, reported the outcomes of its 2025 Annual General Meeting (AGM) held on June 12, 2025. The meeting saw a significant turnout with over 62 million ordinary shares represented in person or by proxy.
The AGM’s agenda included the election and re-election of board members and the appointment of auditors, among other proposals. All resolutions were passed, including the re-election of directors Thomas Lönngren, Robert McQuade, Kabir Nath, and Gino Santini. Additionally, PricewaterhouseCoopers LLP was re-appointed as UK statutory auditors and ratified as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
Shareholders authorized the Audit and Risk Committee to determine the auditors’ remuneration for the year ending December 31, 2025, and approved the receipt of the UK statutory annual accounts and reports for the year ended December 31, 2024. On an advisory basis, the directors’ remuneration report for the year ended December 31, 2024, was also approved.
Furthermore, the AGM granted the directors authority to allot shares and disapply statutory pre-emption rights up to a specified nominal amount. The compensation of the company’s named executive officers for the year ended December 31, 2024, was approved on a non-binding, advisory basis.
The filing indicated that all proposals were duly passed, and the details of the votes were transparently provided. This information is based on a press release statement from COMPASS Pathways plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.